Use of cytological samples of metastatic melanoma for ancillary studies

Abstract

Cytological samples are a reliable and sufficient source for IHC and subsequent molecular analysis, allowing a reduced diagnostic time and rapid, appropriate treatment options in patients with advanced melanoma.

Metastatic neoplasms to the pancreas diagnosed by fine‐needle aspiration/biopsy cytology: A 15‐year retrospective analysis

“…Because it further ensures that the lesion is correctly targeted, ROSE, in conjunction with EUS‐FNA, permits retrieval of ample sufficient tissue for ancillary testing with IHC. Furthermore, many cancers, such as melanoma and lung, gastric, and colon adenocarcinomas, now require the addition of reflex molecular testing to further guide patient treatment and management . Therefore, EUS‐FNA in conjunction with ROSE is of great utility in assuring specimen adequacy in the setting of metastatic disease to the pancreas.…”

“…In addition, both tumors may form true rosettes or pseudorosettes . In contrast, the classic salt‐and‐pepper chromatin pattern of pancreatic neuroendocrine tumor is not a common feature of olfactory neuroblastoma, whereas neurofibrillary matrix has not been observed in the former . Well‐differentiated pancreatic neuroendocrine neoplasms may stain positively for synaptophysin, chromogranin A (Figure E), and CD56 (Figure C) .…”

“…Immunohistochemical staining may be employed for definitive diagnosis, especially in the setting of a poorly differentiated tumor . Authors frequently utilized S‐100, HMB‐45, Melan‐A,, SOX‐10, and rarely MART‐1 …”

Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review

“…Not least, FNA has sampling limitations and samples used for cytologic analysis might be insufficient for further molecular analyses. 8 Imaging modalities (ie, Ultrasound [US], Computed Tomography [CT], Magnetic Resonance Imaging [MRI], Positron Emission Tomography [PET], as well as hybrid modalities) have maintained over the time a crucial role in clinical practice for monitoring therapy even if until few years ago radiological images evaluation was based mainly on qualitative assessment and dimensional measurements. 9 This happened mainly because diagnostic imaging has the advantages of being accurate, minimally invasive, reproducible and presents higher patient compliance for monitoring tumor evolution.…”

“…Moreover, the current model represented by one sampling from a single metastatic site could not intercept all subclones generated because of the rapid evolution of the tumor over time. Not least, FNA has sampling limitations and samples used for cytologic analysis might be insufficient for further molecular analyses …”